Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Non-Current Deffered Revenue (2020 - 2022)

Lyell Immunopharma (LYEL) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $37.2 million as the latest value for Q3 2022.

  • Quarterly Non-Current Deffered Revenue fell 54.61% to $37.2 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $37.2 million through Sep 2022, down 54.61% year-over-year, with the annual reading at $79.7 million for FY2021, 10.56% down from the prior year.
  • Non-Current Deffered Revenue hit $37.2 million in Q3 2022 for Lyell Immunopharma, up from $32.9 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $89.1 million in Q4 2020 to a low of $32.9 million in Q2 2022.
  • Historically, Non-Current Deffered Revenue has averaged $68.6 million across 3 years, with a median of $79.7 million in 2021.
  • Biggest five-year swings in Non-Current Deffered Revenue: fell 10.56% in 2021 and later crashed 59.79% in 2022.
  • Year by year, Non-Current Deffered Revenue stood at $89.1 million in 2020, then decreased by 10.56% to $79.7 million in 2021, then crashed by 53.35% to $37.2 million in 2022.
  • Business Quant data shows Non-Current Deffered Revenue for LYEL at $37.2 million in Q3 2022, $32.9 million in Q2 2022, and $77.9 million in Q1 2022.